Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous Close | 39.33 |
| Open | 39.30 |
| Bid | 39.31 x 37000 |
| Ask | 39.38 x 43000 |
| Day's Range | 38.72 - 39.60 |
| 52 Week Range | 36.90 - 59.70 |
| Volume | |
| Avg. Volume | 5,035 |
| Market Cap | 79.645B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.90 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 2.23 (5.68%) |
| Ex-Dividend Date | Jul 05, 2024 |
| 1y Target Est | N/A |
ZacksInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ZacksBristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
ZacksBristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
© 2024 Yahoo. All rights reserved.